Detailed Narrative
Kerala Cluster's Record Performance and Recovery
The Kerala cluster re-established itself as a primary growth engine, delivering its highest-ever quarterly revenue of ₹620 crore, a 24% increase over Q4 FY25. This recovery was driven by a 13% sequential increase in inpatient volumes and a massive 67% QoQ rebound in Medical Value Travel (MVT). Operating EBITDA margins in the cluster expanded to 26.8%, supported by a stronger specialty mix and disciplined cost control following leadership transitions earlier in the year.
Strategic Merger with Quality Care India (QCIL)
The merger process with QCIL has advanced significantly, receiving no-objection letters from BSE and NSE. The combined proforma platform already demonstrates strong unit economics with a 23% operating EBITDA margin and ROCE exceeding 22%. Upon completion, the merged entity will operate 38 hospitals across 27 cities with a combined capacity of over 10,360 beds, positioning Aster among India's top healthcare providers.
Aggressive Capacity Expansion Roadmap
Aster is entering a phase of accelerated scale, with plans to add over 4,000 beds in the coming years. Aster standalone will add 2,300+ beds (including the recently commissioned 264-bed Kasaragod facility), while QCIL plans a ₹2,000 crore investment to add 1,700 beds. Notably, ~1,300 of the QCIL beds will be added in Tier-2 markets, where management has seen faster scale-up and profitability, as evidenced by the Nagercoil unit becoming EBITDA positive in just three months.
Operational Efficiency and Margin Levers
Management highlighted multiple strategic levers for margin expansion, including a 100-basis-point reduction in overhead costs through centralized procurement and renewable energy. The company has commissioned 13 MW of renewable energy projects and plans an additional 21 MW by early next year. Furthermore, the turnaround of Aster Labs, which saw margins jump to 17.8% from 11.0% YoY, contributes to the overall improvement in consolidated profitability.
Specialty Mix Shift Toward High-Acuity Care
A deliberate shift toward complex, high-value care is evident in the 26% YoY growth of Oncology revenue. Oncology's share of total revenue rose to 11%, up from 9% a year ago. While this shift increases material costs due to expensive immunotherapy drugs, it significantly boosts ARPP (IP) and long-term patient retention. Management expects ARPP to continue growing at a 7-8% CAGR over the next 2-3 years as the specialty mix further matures.